Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone

NCT01263951 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Differentiated Thyroid Cancer

Interventions

DRUG: Everolimus
DRUG: Sorafenib

Sponsor

Thomas Jefferson University

Collaborators

[object Object]
[object Object]